Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Kintara Therapeutics, Inc. (KTRA)

7.08   0.52 (7.93%) 02-02 15:59
Open: 6.65 Pre. Close: 6.56
High: 7.2202 Low: 6.5
Volume: 13,458 Market Cap: 11(M)

Technical analysis

as of: 2023-02-02 3:43:17 PM
Overall:       
Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time.
Target: Six months: 8.99     One year: 10.51
Support: Support1: 5.59    Support2: 4.65
Resistance: Resistance1: 7.69    Resistance2: 9
Pivot: 6.53
Moving Average: MA(5): 6.52     MA(20): 6.86
MA(100): 6.58     MA(250): 10.39
MACD: MACD(12,26): -0.4     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 43.3     %D(3): 35.3
RSI: RSI(14): 49.7
52-week: High: 42  Low: 0.18
Average Vol(K): 3-Month: 403 (K)  10-Days: 29 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ KTRA ] has closed below upper band by 28.1%. Bollinger Bands are 50.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.65 - 6.67 6.67 - 6.7
Low: 6.35 - 6.38 6.38 - 6.41
Close: 6.51 - 6.55 6.55 - 6.6

Company Description

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Headline News

Thu, 02 Feb 2023
Where Does Wall Street Think Kintara Therapeutics Inc (KTRA) Stock Will Go? - InvestorsObserver

Tue, 31 Jan 2023
Should You Buy Kintara Therapeutics Inc (KTRA) in Biotechnology ... - InvestorsObserver

Thu, 26 Jan 2023
Healthcare Stocks Moving Thursday: SCLX, KALA, KTRA, SNOA, OCUP, THMO, FNA, SHPH - InvestorsObserver

Tue, 10 Jan 2023
Kintara Therapeutics to Present at the Biotech Showcase ... - PR Newswire

Thu, 15 Dec 2022
Kintara Therapeutics Receives Orphan Drug Designation for VAL ... - PR Newswire

Tue, 29 Nov 2022
Should You Buy Kintara Therapeutics Inc (KTRA) Stock on Tuesday? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 49 (M)
Shares Float 79 (M)
% Held by Insiders 6.3 (%)
% Held by Institutions 4.6 (%)
Shares Short 688 (K)
Shares Short P.Month 809 (K)

Stock Financials

EPS -0.9
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.12
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -96.2
Return on Equity (ttm) -202.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.47
Qtrly Earnings Growth 0
Operating Cash Flow -20 (M)
Levered Free Cash Flow -11 (M)

Stock Valuations

PE Ratio -7.72
PEG Ratio 0
Price to Book value 53.38
Price to Sales 0
Price to Cash Flow -16.53

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-05-07
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.